Joanna Togami, MD
Urology · New Orleans, LANPI 1366475360
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,462 of the $9,720 with a category attached, or 66.5%. 15 manufacturers reported payments, led by Axonics, Inc. at 48.6% of the total. Reporting peaked in 2024 at $3,316 and has fallen 71.8% since, to $935 in 2025.
Across 145 payments — averaging $67.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- Medtronic$2K
- Boston Scientific$930
- Sumitomo Pharma America, Inc.$499
- Cook Medical LLC$336
- Astellas Pharma US Inc$290
- plus $767 from 9 others
What the payments were for
- Consulting fees$98410%
- Travel & lodging$2,03121%
- Food & beverage$6,46266%
- Education$2432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 77 | $4,723 |
| Medtronic(2 entities) | 21 | $2,175 |
| Boston Scientific | 18 | $930 |
| Sumitomo Pharma America, Inc. | 5 | $499 |
| Cook Medical LLC | 7 | $336 |
| Astellas Pharma US Inc | 5 | $290 |
| Kerecis Limited | 1 | $172 |
| KARL Storz Endoscopy-america | 1 | $150 |
| Olympus America Inc. | 1 | $140 |
| Coloplast | 2 | $135 |
| Progenics Pharmaceuticals, Inc. | 1 | $53 |
| AbbVie(2 entities) | 3 | $53 |
| Urogen Pharma, Inc. | 1 | $28 |
| Procept Biorobotics Corporation | 1 | $20 |
| Coopersurgical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$3,027
- Bulkamid$1,848
- INTERSTIM$1,579
- Kerecis SurgiClose$687
- GEMTESA$343
- Axonics r-SNM System$292
- INTERSTIM ICON$239
- Kerecis GraftGuide$172
- N/A$150
- iTIND System$140
- Cook$130
- AMS 700$130
- SUPRIS$128
- GENERAL MALE SUI$124
- LithoVue$122
- RESONANCE$121
- AMS$114
How this compares
$9,720 in reported general payments places this provider in the 80th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 503 | $288,330 |
| GemtesaVibegron | 114 | $66,532 |
| Estradiol | 418 | $26,635 |
| ElmironPentosan Polysulfate Sodium | 12 | $23,579 |
| EstringEstradiol | 30 | $15,718 |
| Mirabegron ErMirabegron | 24 | $9,677 |
| IntrarosaPrasterone (Dhea) | 13 | $5,414 |
| Methenamine Hippurate | 88 | $4,801 |
| Trospium Chloride | 79 | $4,731 |
| Tolterodine Tartrate ErTolterodine Tartrate | 77 | $3,432 |
| Darifenacin ErDarifenacin Hydrobromide | 43 | $2,476 |
| Trospium Chloride ErTrospium Chloride | 13 | $1,948 |
| Oxybutynin Chloride ErOxybutynin Chloride | 142 | $1,578 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 28 | $1,558 |
| Solifenacin Succinate | 47 | $1,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $290 | $288,330503 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $499 | $66,532114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Alexis ChesrowNew Orleans$17K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.